Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 22,242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Alzheimer Disease, Dementia
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 89 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Coronary Disease
Interventions: placebo, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 30 Years and older
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 17
States / cities: Sun City, Arizona • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Acromegaly
Interventions: IONIS-GHR-LRx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 3 more

Conditions: Prostate Cancer
Interventions: Cryopreserved Umbilical Cord Allograft, Robot-Assisted Radical Prostatectomy; Biological · Procedure
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 30 Years to 70 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Dry Eye Disease
Interventions: GRF312 5%, Placebo Comparator; Drug · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Glendale, California • Grove, California • Newport Beach, California + 7 more

Conditions: Oral Mucositis
Interventions: SGX942, Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Coronavirus Infection
Interventions: NasoVAX, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Miami, Florida • Morrow, Georgia • Chicago, Illinois + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, dose level 1, dose level 2, dose level 3, dose level 4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Daytona Beach, Florida • Ormond Beach, Florida • Duncansville, Pennsylvania

Conditions: Neonatal Abstinence Syndrome, Substance Withdrawal, Neonatal
Interventions: Music Therapy; Other
Lead sponsor: Tulane University; Other
Eligibility: 1 Minute to 1 Month
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Healthy
Interventions: Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Inflammatory Bowel Diseases
Interventions: MyChart Disease Specific; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 197
States / cities: Huntsville, Alabama • Scottsboro, Alabama • Tuscumbia, Alabama + 150 more

Conditions: Healthy Lifestyle, Home Environment Related Disease, Cardiometabolic Disease, Systemic Inflammatory Response, Health Behavior, Dietary Habits, Physical Inactivity, Self Efficacy, Gut Microbiota, Diabetes Mellitus
Interventions: HomeStyles-China; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 30 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Aging, Mild Cognitive Impairment
Interventions: Conversational Engagement; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 75 Years and older
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Healthy Volunteers
Interventions: Samidorphan, Placebo, Oxycodone; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Females
Interventions: PF-04965842, Ethinyl estradiol (EE) and levonorgestrel (LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Sexually Transmitted Infections (Not HIV or Hepatitis), HIV Infections, Sexual Behavior
Interventions: IMARA for Black Male Caregivers and Girls Empowerment, Time-matched control program; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 13 Years and older
Enrollment: 612 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Renal Transplant Donor of Left Kidney, Renal Transplant Donor of Right Kidney
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years and older
Enrollment: 4,415 participants
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Restless Legs Syndrome
Interventions: Pramipexole; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 52
States / cities: Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 47 more

Conditions: Fatigue
Interventions: Acupuncture and patient education; Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Overdose
Interventions: Brief youth overdose prevention education, Usual Standard of Care; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 13 Years and older
Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Social Needs, Health-Related Social Needs, Social Determinants of Health (SDOH), Social Needs Status, Conditions Influencing Health Status, Navigation
Interventions: Active Assistance by Navigators, Passive Referral; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 1,880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Oakland, California • San Francisco, California • Philadelphia, Pennsylvania + 1 more

Conditions: Acne Vulgaris
Interventions: B244, Placebo; Drug
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Richardson, Texas

Search by objective public record fields.

Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

Wearable Assessments in the Clinic and Home in PD

Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis

The Effect of Music Therapy on Newborns

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

MyChart in Patients With Inflammatory Bowel Disease.

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

HomeStyles-Adults of Chinese Heritage

Internet-based Conversational Engagement Clinical Trial

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)

Fractures and Bone Disease in Living Kidney Donors

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors

A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk Aim 3

The Social Needs Assistance for Hospitalized Kids Trial

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris